权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Mechanism-based approach to combine histone deacetylase inhibitors with PARP inhibitors for therapy in AML

基于机制的组蛋白脱乙酰酶抑制剂与 PARP 抑制剂联合治疗 AML

基本信息

批准号：
9318753
负责人：
FEYRUZ VIRGILIA RASSOOL
金额：
$ 20.15万
依托单位：
UNIVERSITY OF MARYLAND BALTIMORE
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-05-01 至 2019-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9318753
关键词：
Acetylation Acute Myelocytic Leukemia Acute leukemia Apoptosis Binding Binding Proteins Biological Assay Bone Marrow Cell Line Cells Chromatin Clinical Combined Modality Therapy Complementary DNA DNA Damage DNA Double Strand Break DNA Repair DNA Repair Gene DNA-PKcs Data Development Dose Double Strand Break Repair EP300 gene Evaluable Disease FDA approved Future Histone Deacetylase Inhibitor Histones In Vitro Ku Protein Ku70 protein Lysine Malignant Neoplasms Measures Mediating Molecular Monitor Mutate Nonhomologous DNA End Joining Pathway interactions Patients Pharmaceutical Preparations Play Poly(ADP-ribose) Polymerases Publications Publishing Reporter Role Sampling Site Testing Therapeutic Transferase Translating Treatment Efficacy Validation Vorinostat XRCC5 gene Xenograft Model base bioluminescence imaging chemotherapeutic agent chemotherapy clinical application clinically relevant combinatorial cytotoxic cytotoxicity improved in vivo inhibitor/antagonist knock-down leukemia mouse model mutant novel novel therapeutics overexpression repaired stable cell line synergism

项目摘要

Project Summary Histone deacetylase inhibitors (HDACi) are in clinical use in leukemias in combination with agents, such as, chemotherapies. Elucidating their mechanisms of action will lead to mechanism-based combination therapy strategies. Our recently published data suggests a novel mechanism through which HDACi could mediate cytotoxicity. We demonstrate that HDACis differentially acetylate not only NHEJ proteins Ku70/Ku80, but also poly ADP-ribose polymerase-1 (PARP1), known to compete with Ku proteins for binding DSBs. An important finding is that PARP1 binding to chromatin increases with duration of HDACis exposure, resembling PARP “trapping” recently demonstrated with PARP inhibitors. PARP1 knockdown inhibits chromatin trapping and mitigates HDACis effect on NHEJ. Moreover, HDACis combined with the potent PARP inhibitor (PARPi) BMN673 induce a dose-dependent increase in PARP trapping. These results provide a new mechanism by which HDACis both acetylate PARP1 and increase binding of PARP1 to DSBs, leading to decreased access of C-NHEJ factors to DNA damage sites, decreasing repair of cytotoxic DSBs in leukemia cells. Validation of this novel concept through the studies we propose, will provide a compelling mechanism-based approach for combining HDACis with PARPis to enhance cell cytotoxicity in acute leukemias. In this proposal we will focus on acute myeloid leukemia (AML) for which novel therapies are needed, to test the central hypothesis that clinically relevant HDACis can cause cytotoxic DSBs through acetylation of PARP1, leading to PARP trapping in chromatin. HDACis in combination with PARPis will enhance PARP trapping in AML cells leading to increased cell cytotoxicity. In specific aim 1, we will determine the extent to which acetylation of PARP1 induced by HDACis contributes to PARP trapping and decreased NHEJ activity. To elucidate the precise molecular steps leading to PARP trapping in chromatin and decreased NHEJ activity, we will use “state of the art” assays and study clinically- relevant HDACis in AML cell lines stably knocked down for PARP1 and the effects of over-expressing PARP1 mutants of 3 key lysine residue targets of acetylation. In specific aim 2, we will determine the sensitivity of HDACis in combination with PARPis in primary AML cells in vitro and in vivo. We will use “state of the art” primary mouse models to study the effects of these inhibitors. These studies will elucidate new mechanisms involving HDACis that will lead to future mechanism-based clinical strategies to combine HDACis with PARPis as a therapy approach in leukemias and other cancers.

项目总结